Enhancing anti-tumor T cell immunity with checkpoint inhibitor antibodies such as anti- cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti- program death 1 (PD-1) has shown significant clinical benefits in tumor regression and prolonged stabilization of non-small cell lung cancer, melanoma, and renal cell cancer(1,2) .
Clinical trials of CTLA-4 and PD1 antibodies excluded patients receiving immunosuppression medications for organ transplantation(3) . Therefore, the adverse events related to CTLA4 and PD-1 antibody treatment in kidney transplant recipients with metastatic cutaneous melanoma have not been examined. This article is protected by copyright. All rights reserved.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2016 Jan 11 [Epub ahead of print]
Tarek Alhamad, Karthikeyan Venkatachalam, Gerald P Linette, Daniel C Brennan
Renal Division, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO. , Renal Division, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO. , Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO. , Renal Division, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO.